Compare ProShares UltraPro S&P500 (UPRO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro S&P500 vs Zimmer Biomet Holdings Inc — how do they compare? ProShares UltraPro S&P500 trades at $154.5, while Zimmer Biomet Holdings Inc trades at $97.1 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| UPRO | ZBH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $155.10 | $107.71 |
52-Week Low | $89.29 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UPRO, a leveraged ETF tracking the S&P 500, trades at $154.9 with a slight 0.06% decline. Technical indicators show a bullish trend with strong moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. Support lies at $152, with resistance at $155. Recent news highlights institutional buying and S&P 500 volatility amid inflation data and AI-driven earnings optimism.
The outlook for UPRO hinges on S&P 500 momentum, with bullish technicals but overbought risks. Upside potential exists if the index breaks resistance, but high leverage amplifies losses during pullbacks. Key risks include market volatility, inflation concerns, and stretched valuations. Investors should weigh the ETF's leveraged structure against broader market trends.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
